EZH2型
癌症研究
生发中心
B细胞
生物
淋巴瘤
作者
Franck Morschhauser,Gilles Salles,Connie Lee Batlevi,Hervé Tilly,Aristeidis Chaidos,Tycel Phillips,John M. Burke,Ari Melnick
出处
期刊:Blood Reviews
[Elsevier]
日期:2022-11-01
卷期号:56: 100988-100988
被引量:6
标识
DOI:10.1016/j.blre.2022.100988
摘要
Enhancer of zeste homolog 2 (EZH2) is an epigenetic regulator that controls the normal biology of germinal B cells. Overexpression or mutation of EZH2 is associated with malignant transformation in a number of B-cell malignancies; thus, EZH2 inhibitors are an attractive therapeutic option for these targets. Several EZH2 inhibitors have entered clinical trials, but there remains an important question as to how EZH2 inhibitor mechanism of action differs in patients with mutant and wild-type EZH2. This review discusses the EZH2-driven mechanisms that lead to the development of B-cell lymphomas and act as therapeutic targets. Another key area of investigation is whether EZH2 inhibitors will work synergistically with existing immunomodulatory drugs and chemotherapy regimens. In summary, EZH2 inhibitors show potential as treatment for a range of B-cell lymphomas, and numerous clinical evaluations are currently underway.
科研通智能强力驱动
Strongly Powered by AbleSci AI